Respiratory syncytial virus immune globulin intravenous

Annals of Pharmacotherapy

Volumn 31, Issue 1, 1997, Pages 83-88

  Wandstrat, Todd L ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG DYSPLASIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VACCINATION; VIRUS INFECTION; VOMITING; WHEEZING;

EID: 0031027056     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100114     Document Type: Review

References (36)

1. Hellman CA. Respiratory syncytial virus and parainfluenza viruses. J Infect Dis 1990:161:402-6.
2. Meissner HC. Economic impact of viral respiratory disease in children. J Pediatr 1994;124(suppl):S17-21.
3. Cunningham CK, McMilJan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks gestation. Pediatrics 1991;88:527-32.
4. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JC, eds. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders, 1992;1633-56.
5. Hall CB. Respiratory syncytial virus: what we know now. Contemp Pediatr 1993;10(11):2-11.
6. American Academy of Pediatrics, Committee of Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytiaJ virus infections. Pediatrics 1996;97:137-40.
7. Meissner HC, Fulton DR, Groothuis JR, Geggel RL, Marx GR, Hemming VG, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial vims disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993;37:1655-8.
8. Mclntosh K. Respiratory syncytial virus - successful immunoprophylaxis at last. N EngI J Med 1993;328:1572-4.
9. Stiehm ER. Passive immunization. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders, 1992:2261-88.
10. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976;134:211-7.
11. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973;98:289-300.
12. Hemming VG, Rodriguez W. Kim HW, Brandt CD, Parrott RH, Burch B, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother 1987;31:1882-6.
13. Groothuis JR, Levin MJ, Rodriguez W, Hall CB, Long CE. Kim HW, et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother 1991;35:1469-73.
14. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995;8:22-33,
15. Horowitz B, Wiebe ME, Lippin A. Inactivation of viruses in labile blood derivatives. Transfusion 1985;25:515-22.
16. Package insert. RespiGam (respiratory syncytial virus immune globulin intravenous). Gaithersburg, MD: Medlmmune, Inc. 1996.
17. Groothuis JR, Simoes EAF, Lehr MV, Kramer AA, Hemming VG, Rodriguez WJ, et al. Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin. Antimicrob Agents Chemother 1995;39:688-71.
18. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long C, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
19. Connor EM. Reduction of respiratory syncytial virus-associated hospitalization in children with premature birth and/or bronchopulmonary dysplasia using monthly infusions of RSV immune globulin (abstract). Pediatr Res 1996;39:1000.
20. Simoes EAF, Sondheimer HM, Meissner HC, Welliver RC, Groothuis JR. Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease (abstract). Pediatr Res 1996;39:662.
21. Rodriguez WJ, Gruber WC, Groothuis J, Rosas AJ, Lepow M, Hemming V, et al. Respiratory syncytial virus immune human globulin (RSVIg) as treatment of RSV lower respiratory tract infections (LRI) in children (abstract). Pediatr Res 1996;39:1085.
22. Meert K, Heidemann S, Lieh-Lai M, Sarnaik AP. Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised hosts. Pediatr Pulmonol 1989;7:167-70.
23. Groothuis JR, Simoes EAF, Hemming VG, Respiratory Syncytial Virus Immune Globulin Study Group. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 1995;95:463-7.
24. Ellenberg SS, Epstein JS, Fratantoni JC, Scott D, Zoon KC. A trial of RSV immune globulin in infants and young children: the PDA's view (letter). N Engl J Med 1994;331:203-4.
25. Groothuis JR, Hemming VG, Siber GR, Top FH. Authors' reply (letter). N Engl J Med 1994;331:204-5.
26. Feldstein TJ, Swegarden JL, Atwood GF, Peterson CD. Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy. Pediatrics 1995;96:14-7.
27. Gadomski AM. Lichenstein R, Horton L, King J, Keane V, Permutt T. Efficacy of albuterol in the management of bronchiolitis. Pediatrics 1994;93:907-12.
28. Grier CF, Howe BJ. Economic impact of pneumonia due to respiratory syncytial virus (RSV) infection (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, October 1995.
29. Smith DW, Frankel LR, Mathers LH, Tang ATS, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24-9.
30. Wojtynek JE. Respiratory syncytial virus-immune globulin (RespiGam). J Pediatr Pharm Pract 1996;1:1-9.
31. Kaplan B, Wandstrat TL. Pharmacoeconomic considerations in the treatment of otitis media (abstract). Presented at the Academy of Managed Care Pharmacy, Anaheim, CA, October 1994.
32. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care 1996;2:851-61.
33. Sigurs N, Bjamason R, Sigurbergsson F, Kjellman B, Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995;95:500-5.
34. Advisory Committee on Immunization Practices. Update: vaccine side effects, adverse reactions, contraindications, and precautions. MMWR Morb Mortal Wkly Rep 1996;45(RR-12):1-35.
35. Hinman AR, Orenstein WA. Public health considerations. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphia: WB Saunders, 1994:903-32.
36. Committee on Infectious Diseases, American Academy of Pediatrics. 1994 Red book: report of the Committee on Infectious Diseases. 23rd ed. Elk Grove, IL: American Academy of Pediatrics, 1994:28.